Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Amortization of Deferred Charges (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Amortization of Deferred Charges data on record, last reported at $495000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 14.06% year-over-year to $495000.0; the TTM value through Dec 2025 reached $3.4 million, down 9.03%, while the annual FY2025 figure was $3.4 million, 9.03% down from the prior year.
  • Amortization of Deferred Charges reached $495000.0 in Q4 2025 per OCUL's latest filing, down from $758000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.1 million in Q3 2023 and bottomed at $495000.0 in Q4 2025.
  • Average Amortization of Deferred Charges over 5 years is $1.1 million, with a median of $1.2 million recorded in 2021.
  • Peak YoY movement for Amortization of Deferred Charges: soared 69.14% in 2023, then plummeted 70.03% in 2024.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $1.2 million in 2021, then grew by 4.12% to $1.2 million in 2022, then increased by 25.55% to $1.6 million in 2023, then plummeted by 62.91% to $576000.0 in 2024, then fell by 14.06% to $495000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $495000.0 in Q4 2025, $758000.0 in Q3 2025, and $708000.0 in Q2 2025.